WuXi AppTech acquired HD Biosciences, a preclinical drug-discovery-focused CRO.
On Jan. 19, 2017 WuXi AppTec announced the acquisition of the biology-focused preclinical drug discovery contract research organization (CRO), HD Biosciences (HDB). After completion of the acquisition, HDB will become a wholly-owned subsidiary of WuXi. The company did not disclose the financial terms of the acquisition.
HBD is headquartered in Shanghai and has operating facilities in Beijing and San Diego, CA. HBD offers? plate-based pharmacology and screening capabilities, hit identification, lead discovery, and in vivo pharmacology, among other services. In a statement, WuXi said the acquisition will further strengthen its R&D capability from target validation to lead discovery and optimization, expanding WuXi's open-access enabling service platform.
